PropThink: Diabetes, Carcinoid Syndrome Drive Lexicon’s Late-Stage Pipeline

[ACN Newswire] – By Jake KingTwo pertinent announcements from Lexicon Pharmaceuticals (NASDAQ:LXRX) are giving shares a 7% lift on Friday morning. The company reported top-line data from the latest Phase II trial of telotristat … more

View todays social media effects on LXRX

View the latest stocks trending across Twitter. Click to view dashboard